Drug Search Results
More Filters [+]

Trevogrumab

Alternative Names: trevogrumab, regn1033, sar391786
Latest Update: 2024-07-03
Latest Update Note: Clinical Trial Update

Product Description

Mechanisms of Action: GDF8 Inhibitor

Novel Mechanism: Yes

Modality: Antibody

Route of Administration: Intravenous,Subcutaneous

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Regeneron
Company Location: TARRYTOWN NY 10591
Company CEO: Leonard S. Schleifer
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Trevogrumab

Countries in Clinic: United States

Active Clinical Trial Count: 1

Highest Development Phases

Phase 2: Obesity

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

COURAGE

P2

Recruiting

Obesity

2026-06-24

Recent News Events